Annual Meeting 2012 Program: Special Sessions

Special Sessions

AACR Annual Business Meeting

Drug Development Track: New Drugs on the Horizon 1
Co-Chairpersons: Lori S. Friedman, Genentech, Inc., South San Francisco, CA; and Simon Bailey, Pfizer, Inc., San Diego, CA

• Christine M. Fritsch, Novartis AG, Basel, Switzerland
• Katherine Galvin, Millennium Pharmaceuticals, Cambridge, MA
• Suresh G. Shelat, Bristol-Myers Squibb, Princeton, NJ
• Richard Wooster, GlaxoSmithKline, Collegeville, PA

Drug Development Track: New Drugs on the Horizon 2
Co-Chairpersons: Nancy K. Pryer, Novartis, Emeryville, CA; and Stacie S. Canan, Celgene Corp., San Diego, CA

• Laurent R. DeBussche, Sanofi, Vitry-sur-Seine, France
• Steven W. Elmore, Abbott Laboratories, Abbott Park, IL
• Sarah A. Loddick, AstraZeneca, Macclesfield, United Kingdom
• Paul G. Polakis, Genentech, Inc., South San Francisco, CA 

Joint Cancer Immunology (CIMM)/Tumor Microenvironment (TME) Working Group Evening Scientific Session
Co-Chairpersons: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA; and Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA

• Frances R. Balkwill, Barts Cancer Institute, London, United Kingdom
• Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA
• Harold L. Moses. Vanderbilt-Ingram Cancer Center, Nashville, TN

Love/Avon Army of Women Panel Discussion: Crossing the Chasm from Animal Models to Women

• Susan E. Clare, Indiana University School of Medicine, Indianapolis, IN
• Carla V. Finkielstein, Virginia Polytechnic Institute and State University, Blacksburg, VA
• Olympia Kalagidis, Dr. Susan Love Research Foundation, Santa Monica, CA
• Susan Love, Dr. Susan Love Research Foundation, Santa Monica, CA
• Carlos Sonnenschein, Tufts University School of Medicine, Boston, MA

Meet the AACR Chief Executive Officer: Margaret Foti

Meet the Minorities in Cancer Research (MICR) Council
Chairperson: Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

Meet the New AACR President: Frank McCormick

Meet the Women in Cancer Research (WICR) Council
Co-Chairpersons: Lydia Armstrong, Novartis, Florham Park, NJ; Ann D. Thor, University of Colorado Denver School of Medicine, Aurora, CO; and Worta McCaskill-Stevens, National Cancer Institute, Bethesda, MD

NCI Update

• Douglas R. Lowy, National Cancer Institute, Bethesda, MD

Pancreatic Cancer Action Network-AACR Grantee Poster Presentation and Discussion Session
Co-Moderators: Dafna Bar-Sagi, New York University School of Medicine, New York, NY; and Lynn M. Matrisian. Pancreatic Cancer Action Network, Manhattan Beach, CA

• Jennifer M. Bailey, Johns Hopkins University, Baltimore, MD
• Jonathan R. Brody, Thomas Jefferson University, Philadelphia, PA
• Lisa A. Cannon-Albright, University of Utah Health Sciences Center, Salt Lake City, UT
• Cosimo Commisso, New York University School of Medicine, New York, NY
• James R. Eshleman, Johns Hopkins University School of Medicine, Baltimore, MD
• Dimitrios Iliopoulos, Dana-Farber Cancer Institute, Boston, MA
• Alec Kimmelman, Dana-Farber Cancer Institute, Boston, MA
• Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, NY
• Hidde L. Ploegh, MIT Whitehead Institute for Biomed. Research, Cambridge, MA
• E. Scott Seeley, Stanford University School of Medicine, Stanford, CA
• Michael N. VanSaun, Vanderbilt University, Nashville, TN

Scientist↔Survivor Program Advocates Poster Session

Special Symposium: Clinical Trials of Agents Directed Towards PI3K and Metabolic Pathways
Chairperson: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

• Fabrice Andre, Institut Gustave-Roussy, Villejuif, France
• Carlos L. Arteaga
• Lewis C. Cantley, Harvard Medical School/Beth Israel Deaconess Medical Center, Boston, MA
• Lillian L. Siu, University Health Network Ontario Cancer Institute, Toronto, ON, Canada

Special Symposium: Clinical Trials of Novel Agents
Chairperson: Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom

• Johann S. de Bono

Special Symposium: Ethical Issues in Genomic Research
Co-Chairpersons: Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Boston, MA; and Walter Wolf, USC School of Pharmacy, Los Angeles, CA

• Robert Cook-Deegan, National Academy Foundation, Washington, DC
• Steven Joffe, Dana-Farber Cancer Institute, Children's Hospital, Harvard Medical School, Boston, MA
• Reed E. Pyeritz, University of Pennsylvania, Philadelphia, PA
• Susan M. Wolf, University of Minnesota, Minneapolis, MN

Special Symposium: Future Leaders in Basic Cancer Research

• Carrie A. Adelman, Cancer Research UK, South Mimms, United Kingdom
• Fiayaz Notta, University of Toronto, Toronto, ON, Canada
• Michael Quante, Columbia University, New York, NY
• David A. Solomon, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

Stand Up To Cancer: Maximizing Innovation Through Translational Research and Team Science
Moderator: Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

• Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD
• Lewis C. Cantley, Harvard Medical School/Beth Israel Deaconess Medical Center, Boston, MA
• Joe W. Gray, OHSU Knight Cancer Institute, Portland, OR
• Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA
• Daniel D. Von Hoff, Translational Genomics Research Institute, Phoenix, AZ

Writing a Successful Career Development Award: Tips and Pitfalls
Co-Sponsored by the Association for Patient-Oriented Research

Science Policy Sessions

Challenging Conventional Cancer Care: The Untold Story of Tobacco’s Effect on Cancer Biology, Treatment Response, and Survival
Chairperson: Roy S. Herbst, Yale Comprehensive Cancer Center, New Haven, CT

• Paul M. Cinciripini, The University of Texas MD Anderson Cancer Center, Houston, TX
• Robert T. Croyle, National Cancer Institute, Bethesda, MD
• Roy S. Herbst
• Benjamin A. Toll, Yale Comprehensive Cancer Center, New Haven, CT
• Graham W. Warren, Roswell Park Cancer Institute, Buffalo, NY

Evolution of Translational Omics – Lessons Learned and the Path Forward: A New Report from the Institute of Medicine

• Joe W. Gray, OHSU Knight Cancer Institute, Portland, OR
• Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
• Gilbert S. Omenn, University of Michigan, Ann Arbor, MI
• Daniela M. Witten, University of Washington, Seattle, WA

From Science to Policy: Challenges in Translating Scientific Evidence into Practice-Changing Clinical Recommendations and Decision Tools

• Joy Melnikow, University of California Davis Medical Center, Sacramento, CA
• David F. Ransohoff, University of North Carolina at Chapel Hill Medical School, Chapel Hill, NC

Funding and Advocacy – Outlook for Cancer Research Funding in 2012 and Beyond: What Deficit Reduction Means for the NIH Budget and What We Can Do About It
Chairperson: Jon G. Retzlaff, American Association for Cancer Research, Washington, DC

• Amy Bulman, National Cancer Institute, Bethesda, MD
• Wendy Selig, Melanoma Research Alliance, Washington, DC

HIPAA: Can It Protect Patients Without Impeding Research?

• Fred H. Cate, Indiana University Maurer School of Law, Bloomington, IN
• Sandra J. Horning, Genentech, Inc., San Francisco, CA

Regulatory Science and Policy Sessions

Codevelopment of Two or More Investigational Drugs
Chairperson: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

• Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA
• Roy S. Herbst, Yale Comprehensive Cancer Center, New Haven, CT
• Stuart G. Lutzker, Genentech Inc., South San Francisco, CA
• Janet Woodcock, U.S. Food and Drug Administration, Silver Spring, MD

Highly Adaptive Trials in Drug Development: Scientific and Regulatory Considerations
Chairperson: Eric H. Rubin, Merck Research Laboratories, North Wales, PA

• Keaven Anderson, Merck Research Laboratories, North Wales, PA
• Stuart Bailey, Novartis, Basel, Switzerland
• Donald A. Berry, The University of Texas MD Anderson Cancer Center, Houston, TX
• Sue-Jane Wang, U.S. Food and Drug Administration, Silver Spring, MD

Meet-the-Expert: Comparative Effectiveness and Implications for Trial Design

• Jan H. M. Schellens, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Pathway vs. Histology in Drug Development

• Grant A. McArthur, Peter MacCallum Cancer Centre, East Melbourne, Australia
• Janet Woodcock, U.S. Food and Drug Administration, Silver Spring, MD

Scientific and Regulatory Challenges in Codevelopment of Predictive In Vitro Diagnostics
Chairperson: Mark J. Ratain, University of Chicago, Chicago, IL

• Janet E. Dancey, Ontario Institute for Cancer Research, Toronto, ON, Canada
• Rachel W. Humphrey, MethylGene Inc., Montreal, QC, Canada
• Samir N. Khleif, Georgia Health Sciences University Cancer Center, Augusta, GA
• Mark J. Ratain